PAQ Therapeutics secures $30 Million to target diseases with limited therapeutic options

Nest.Bio resident company, PAQ Therapeutics, secured $30 million in Series A financing to continue researching autophagy to find solutions for diseases with limited therapeutic options. Autophagy is the body's natural process of purging damaged cells to regenerate new cells. Co-founder and CEO Nan Ji, Ph.D., and co-founder Huaixiang Hao, Ph.D. have curated an international group of autophagy experts. Together they have been developing autophagosome tethering compounds (ATTECs) which catalyze the degradation of disease-causing proteins, lipids, and pathogens. Among the financiers were Sherpa Healthcare Partners, a healthcare-focused venture capital fund, as well as biopharmaceutical tech-focused Matrix Partners China, and Nest.Bio Ventures.

Read their full announcement here...